Moomoo AIのまとめ
On April 10, 2024, Shah Capital Management, Inc., Shah Capital Opportunity Fund LP, and Himanshu H. Shah, collectively referred to as the Reporting Persons, filed a Schedule 13D with the United States Securities and Exchange Commission (SEC) regarding their significant investment in Novavax, Inc. The filing indicates that Shah Capital Management, as an investment adviser, and Shah Capital Opportunity Fund LP, a partnership, along with Himanshu H. Shah, President and Chief Investment Officer of Shah Capital, have acquired substantial shares of Novavax. The Reporting Persons collectively own 9,326,176 shares through Shah Capital Management, 8,700,000 shares through Shah Capital Opportunity Fund LP, and 9,383,335 shares by Himanshu H. Shah individually, representing 6.66%, 6.21%, and 6.70% of the outstanding shares, respectively. The shares were acquired for investment purposes in the ordinary...Show More
On April 10, 2024, Shah Capital Management, Inc., Shah Capital Opportunity Fund LP, and Himanshu H. Shah, collectively referred to as the Reporting Persons, filed a Schedule 13D with the United States Securities and Exchange Commission (SEC) regarding their significant investment in Novavax, Inc. The filing indicates that Shah Capital Management, as an investment adviser, and Shah Capital Opportunity Fund LP, a partnership, along with Himanshu H. Shah, President and Chief Investment Officer of Shah Capital, have acquired substantial shares of Novavax. The Reporting Persons collectively own 9,326,176 shares through Shah Capital Management, 8,700,000 shares through Shah Capital Opportunity Fund LP, and 9,383,335 shares by Himanshu H. Shah individually, representing 6.66%, 6.21%, and 6.70% of the outstanding shares, respectively. The shares were acquired for investment purposes in the ordinary course of business, with no current plans to influence or change the company's operations. The Reporting Persons may engage in discussions with Novavax's management or other stakeholders and may alter their investment strategy based on the company's performance and market conditions. The filing also includes a Joint Filing Agreement and a letter to the Board of Directors (BOD Letter) as exhibits.
2024年4月10日、Shah Capital Management、Shah Capital Opportunity Fund LP、およびHimanshu H. Shahの報告者を含む者が、Novavax、Inc.への重要な投資に関して米国証券取引委員会（SEC）にスケジュール13Dを提出しました。提出により、投資顧問としてのShah Capital Management、パートナーシップであるShah Capital Opportunity Fund LP、およびShah Capitalの社長兼最高投資責任者であるHimanshu H. Shahは、Novavaxの実質的な株式を取得した...すべて展開
2024年4月10日、Shah Capital Management、Shah Capital Opportunity Fund LP、およびHimanshu H. Shahの報告者を含む者が、Novavax、Inc.への重要な投資に関して米国証券取引委員会（SEC）にスケジュール13Dを提出しました。提出により、投資顧問としてのShah Capital Management、パートナーシップであるShah Capital Opportunity Fund LP、およびShah Capitalの社長兼最高投資責任者であるHimanshu H. Shahは、Novavaxの実質的な株式を取得したことが示されています。報告者らは、Shah Capital Managementを通じて932万6176株、Shah Capital Opportunity Fund LPを通じて870万株、Himanshu H. Shah個人が938万3335株を保有し、それぞれ発行済み株式の6.66%、6.21%、および6.70%を所有しています。これらの株式はビジネスの普通の運営のために投資目的で取得され、現在は会社の運営を影響または変更する現在の計画はありません。報告者らは、Novavaxの経営陣やその他の利害関係者との議論に参加し、会社の業績や市況に基づいて自身の投資戦略を変更する可能性があります。提出には、共同記名契約および取締役会への手紙（BOD Letter）も含まれています。
役に立った
役に立たない